Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia

NCT06211634 is registered in ClinicalTrials.gov with Hemab ApS as lead sponsor.

NCT NCT06211634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06211634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-Human, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants With Glanzmann Thrombasthenia
Lead sponsor
Hemab ApS
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 13, 2022
Completion date
August 31, 2027
Enrollment
57 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

glanzmann thrombasthenia